close

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company's preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	16.20
Volume	74672
Volume Avg	55036
52 Week High	18.99
52 Week Low	8.63
PE	N/A
PE (group average)	N/A
EPS Year	-1.51
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-35.42%
EPS change Q/Q next Q est	-55.71%
EPS change Y/Y	-35.76%
REV change Q/Q	-47.83%
REV change Q/Q Yr ago	-74.47%
EPS next Q est	-0.70
EPS next Y est	-2.51
Divident Annual	0.00
Dividend Yield	0%